Cerevance Media Center
Current News
November 13, 2023
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
September 19, 2023
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.
August 28, 2023
Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.
July 10, 2023
Cerevance to Present at the Alzheimers Association International Conference
Cerevance to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.
News Archive
May 9, 2024
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
Cerevance will present an oral presentation at the upcoming International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson’s Disease and Related Disorders, taking place in Lisbon, Portugal from May 19-22, 2024. Karl Kieburtz, MD, MPH, will share Phase 2 study findings that enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.
April 29, 2024
Cerevance to Present at RBC Capital Markets 2024 Global Healthcare Conference
Cerevance company management to present at RBC Capital Markets 2024 Global Healthcare Conference, May 14-15, 2024. Craig Thompson, chief executive officer of Cerevance, will present a company overview on Wednesday, May 15, 2024, at 11:30 am ET. Cerevance management will also participate in one-on-one meetings with investors during the conference.
April 29, 2024
Cerevance to Participate at Wells Fargo Virtual Private Biotech Symposium
Cerevance company management to participate in upcoming Wells Fargo Virtual Private Biotech Symposium, May 6, 2024. Cerevance management will participate in one-on-one meetings with investors during the conference.
April 17, 2024
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
April 2, 2024
Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference
March 13, 2024
Cerevance Announces Presentation at Alzheimer’s Research UK Conference
Events Archive
April 8, 2024
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment
March 15, 2024
Differential contribution of THIK‑1 K+ channels and P2X7 receptors to ATP‑mediated neuroinflammation by human microglia
March 7, 2024
NETSseq reveals deep molecular insights into astrocyte biology and identifies novel therapeutic targets for Alzheimer’s disease
February 12, 2024
Discovery and First-time Disclosure of CVN766, an Exquisitely Selective Orexin 1 Receptor Antagonist
December 25, 2023
NETSseq Advances the Understanding of Neuronal Vulnerability in AD Progression Facilitating the Identification of Novel Therapeutic Targets at the Single Cell Type Level
November 15, 2023